The advent of ICIs in the adjuvant setting has not led to a change in the treatment algorithm for ALK-positive NSCLCs, as there is no clinical evidence supporting a benefit of immunotherapy in NSCLC patients with oncogenic driver mutations. This evidence concerns the gene ALK and non-small cell lung carcinoma.